Venus Medtech (Hangzhou) Inc. (VMTHF)

Market Cap	150.03M
Revenue (ttm)	64.51M
Net Income (ttm)	-97.86M
Shares Out	n/a
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	700
Average Volume	5
Open	0.2871
Previous Close	0.2512
Day's Range	0.2512 - 0.2871
52-Week Range	0.0108 - 0.3938
Beta	0.75
RSI	45.31
Earnings Date	Aug 29, 2025

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Ve...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Employees: 691
• Stock Exchange: OTCMKTS
• Ticker Symbol: VMTHF

Financial Performance

In 2024, Venus Medtech (Hangzhou)'s revenue was 470.83 million, a decrease of -4.18% compared to the previous year's 491.37 million. Losses were -714.31 million, 1.50% more than in 2023.

Financial numbers in CNY